FAM
CLDX icon

Fred Alger Management’s Celldex Therapeutics CLDX Stock Holding History

Fred Alger Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Sell
9,448
-9,006
-49% -$291K ﹤0.01% 405
2026
Q1 		$585K Buy
+18,454
New +$503K ﹤0.01% 376
2023
Q3 		– Sell
-165,317
Closed -$5.61M – 478
2023
Q2 		$5.61M Sell
165,317
-198,956
-55% -$6.71M 0.03% 240
2023
Q1 		$13.1M Sell
364,273
-156,599
-30% -$6.76M 0.07% 179
2022
Q4 		$23.2M Buy
520,872
+77,230
+17% +$2.76M 0.13% 154
2022
Q3 		$12.5M Buy
443,642
+200,259
+82% +$6.14M 0.06% 190
2022
Q2 		$6.56M Buy
243,383
+87,579
+56% +$2.54M 0.03% 239
2022
Q1 		$5.31M Sell
155,804
-346,321
-69% -$11.1M 0.02% 266
2021
Q4 		$19.4M Sell
502,125
-23,742
-5% -$1.03M 0.05% 209
2021
Q3 		$28.4M Buy
+525,867
New +$24.7M 0.07% 189
2016
Q4 		– Sell
-4,000
Closed -$242K – 491
2016
Q3 		$242K Buy
4,000
+453
+13% +$28.2K ﹤0.01% 371
2016
Q2 		$234K Sell
3,547
-12,796
-78% -$812K ﹤0.01% 409
2016
Q1 		$927K Sell
16,343
-6,362
-28% -$716K ﹤0.01% 382
2015
Q4 		$5.34M Sell
22,705
-2,375
-9% -$518K 0.03% 242
2015
Q3 		$3.96M Sell
25,080
-11,626
-32% -$3.29M 0.02% 294
2015
Q2 		$13.9M Sell
36,706
-369
-1% -$147K 0.06% 188
2015
Q1 		$15.5M Sell
37,075
-15,374
-29% -$5.5M 0.07% 209
2014
Q4 		$14.4M Buy
52,449
+7,411
+16% +$1.84M 0.07% 214
2014
Q3 		$8.76M Sell
45,038
-2,186
-5% -$476K 0.04% 279
2014
Q2 		$11.6M Sell
47,224
-1,440
-3% -$325K 0.06% 263
2014
Q1 		$12.9M Sell
48,664
-21,997
-31% -$8.42M 0.06% 274
2013
Q4 		$25.7M Buy
70,661
+46,984
+198% +$18.1M 0.13% 175
2013
Q3 		$12.6M Buy
+23,677
New +$8.12M 0.07% 269

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fred Alger Management's CLDX Position: Q2 2026 in Review

Fred Alger Management reduced its Celldex Therapeutics (CLDX) stake by 49% in Q2 2026, selling an estimated $291K and leaving 9,448 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #405.

Fred Alger Management first reported a position in CLDX in Q3 2013 and has held it in 23 quarters since. The position peaked at $28.4M in Q3 2021. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Fred Alger Management held 9,448 shares of Celldex Therapeutics worth $352K as of Q2 2026.
  • Fred Alger Management sold 9,006 Celldex Therapeutics shares in Q2 2026, an estimated $291K.
  • Celldex Therapeutics made up ﹤0.01% of Fred Alger Management's portfolio in Q2 2026, its #405 holding.
  • Fred Alger Management first reported a position in Celldex Therapeutics in Q3 2013 and has held it in 23 quarters since.
  • Fred Alger Management's Celldex Therapeutics position peaked at $28.4M in Q3 2021.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.